# A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

> **NCT01478685** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 169 (actual)

## Conditions studied

- Urinary Bladder Neoplasms
- Carcinoma, Transitional Cell
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Pancreatic Ductal
- Tumor Virus Infections

## Interventions

- **DRUG:** CC-486
- **DRUG:** Carboplatin
- **DRUG:** ABI-007

## Key facts

- **NCT ID:** NCT01478685
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-29
- **Primary completion:** 2015-11-17
- **Final completion:** 2015-11-17
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478685, "A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01478685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*